Headlands Technologies LLC Decreases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Headlands Technologies LLC trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 90.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 328 shares of the company’s stock after selling 3,148 shares during the quarter. Headlands Technologies LLC’s holdings in Medpace were worth $79,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Altshuler Shaham Ltd bought a new position in Medpace in the 4th quarter worth approximately $27,000. FinTrust Capital Advisors LLC bought a new position in shares of Medpace during the 3rd quarter valued at approximately $30,000. Rockefeller Capital Management L.P. boosted its position in shares of Medpace by 361.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after acquiring an additional 112 shares during the last quarter. Pinebridge Investments L.P. bought a new position in shares of Medpace during the 2nd quarter valued at approximately $35,000. Finally, C M Bidwell & Associates Ltd. bought a new position in shares of Medpace during the 2nd quarter valued at approximately $38,000. 77.98% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 10,391 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $304.15, for a total transaction of $3,160,422.65. Following the transaction, the vice president now owns 17,292 shares of the company’s stock, valued at approximately $5,259,361.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Medpace Investors, Llc sold 33,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $283.42, for a total transaction of $9,352,860.00. Following the sale, the insider now owns 5,856,947 shares of the company’s stock, valued at $1,659,975,918.74. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 10,391 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $304.15, for a total value of $3,160,422.65. Following the sale, the vice president now directly owns 17,292 shares in the company, valued at approximately $5,259,361.80. The disclosure for this sale can be found here. Insiders have sold a total of 185,391 shares of company stock worth $51,630,381 over the last quarter. Company insiders own 25.70% of the company’s stock.

Analyst Ratings Changes

Separately, Robert W. Baird increased their target price on Medpace from $302.00 to $312.00 and gave the company an “outperform” rating in a research report on Wednesday, January 17th.

Read Our Latest Research Report on Medpace

Medpace Stock Performance

NASDAQ:MEDP opened at $324.21 on Tuesday. The stock’s fifty day moving average is $298.50 and its 200 day moving average is $273.53. Medpace Holdings, Inc. has a fifty-two week low of $167.00 and a fifty-two week high of $331.10. The firm has a market capitalization of $9.95 billion, a PE ratio of 37.96 and a beta of 1.29.

Medpace (NASDAQ:MEDPGet Free Report) last released its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. Medpace had a return on equity of 68.48% and a net margin of 15.33%. The business had revenue of $498.40 million for the quarter, compared to analyst estimates of $498.72 million. During the same quarter last year, the firm posted $2.12 earnings per share. The business’s revenue was up 26.5% compared to the same quarter last year. Equities analysts forecast that Medpace Holdings, Inc. will post 8.65 EPS for the current year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

See Also

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.